ID   CEM/VLB100
AC   CVCL_3932
SY   CEM-VLB100; CEM/VLB 100; CEM/VBL 100; CEM-VBL100
DR   BTO; BTO_0005155
DR   cancercelllines; CVCL_3932
DR   ChEMBL-Cells; CHEMBL3988441
DR   Cosmic; 922676
DR   PubChem_Cell_line; CVCL_3932
DR   Wikidata; Q54809282
RX   PubMed=571759;
RX   PubMed=2888532;
RX   PubMed=3469013;
RX   PubMed=9557624;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27375; Vincaleukoblastine (Vinblastine).
CC   Sequence variation: Gene fusion; HGNC; HGNC:13222; BCL11B + HGNC; HGNC:2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Caution: Seems to be interchangeably called VLB100 or VBL100.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0207 ! CCRF-CEM
SX   Female
AG   3Y11M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 28
//
RX   PubMed=3469013;
RA   Danks, Mary K.
RA   Yalowich, Jack Charles
RA   Beck, William T.
RT   "Atypical multiple drug resistance in a human leukemic cell line
RT   selected for resistance to teniposide (VM-26).";
RL   Cancer Res. 47:1297-1301(1987).
//
RX   PubMed=2888532;
RA   Beck, William T.
RA   Cirtain, Margaret Cook
RA   Danks, Mary K.
RA   Felsted, Ronald LaNay
RA   Safa, Ahmad R.
RA   Wolverton, Judith Singer
RA   Suttle, D. Parker
RA   Trent, Jeffrey M.
RT   "Pharmacological, molecular, and cytogenetic analysis of 'atypical'
RT   multidrug-resistant human leukemic cells.";
RL   Cancer Res. 47:5455-5460(1987).
//
RX   PubMed=9557624; DOI=10.1038/sj.leu.2400976;
RA   Mattii, Letizia
RA   Barale, Roberto
RA   Petrini, Mario
RT   "Use of the comet test in the evaluation of multidrug resistance of
RT   human cell lines.";
RL   Leukemia 12:627-632(1998).
//
RX   PubMed=571759;
RA   Beck, William T.
RA   Mueller, Thomas J.
RA   Tanzer, Lee R.
RT   "Altered surface membrane glycoproteins in Vinca alkaloid-resistant
RT   human leukemic lymphoblasts.";
RL   Cancer Res. 39:2070-2076(1979).
//